

Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PCT
#6

TRANSMITTAL FORM (to be used for correspondence after initial filing)	Application Number	09/700,851	
	Filing Date	November 17, 2000	
	First Named Inventor	Matsumoto, Yoh-ichi	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
Total Number of Pages in This Submission	18	Attorney Docket Number	019026-000110US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input checked="" type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard Copy of Notification of Defective Response Sequence Listing CRF of Sequence Listing
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm and Individual name	Townsend and Townsend and Crew LLP Joe Liebeschuetz Reg. No. 37,505	
Signature		
Date	July 19, 2002	

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: BOX SEQUENCE. PO BOX 2327, ARLINGTON, VA 22202 on this date:		
		July 19, 2002
Typed or printed name	Paula Faulk Hurley	
Signature		Date July 19, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3237235 v1



UNITED STATES PATENT AND TRADEMARK OFFICE

019026-000110US JOL

 Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/700,851	Atsuchi Imaizumi	019026 000110US

INTERNATIONAL APPLICATION NO.	
PCT/US99/11179	
I.A. FILING DATE	PRIORITY DATE
05/19/1999	05/20/1998

 Joe Liebeschuetz
 Two Embarcadero Center 8th Floor
 San Francisco, CA 94111


CONFIRMATION NO. 3540

371 FORMALITIES LETTER



OC000000008329865

Date Mailed: 06/21/2002

Response Due 7/21/02 53P
+ Sequence Listing

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Additionally the following defects have been observed:

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the

- computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
 - **APPLICANT MUST PROVIDE:**
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
 - Additional claim fees of **\$552** as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$552** for a Large Entity:

- Total additional claim fee(s) for this application is **\$552**
 - **\$92** for **3** independent claims over 3.
 - **\$180** for **23** total claims over 20.
 - **\$280** for multiple dependant claims surcharge.
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

KAYA L LEWIS BALTIMORE

Telephone: (703) 305-3695


PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/700,851	PCT/US99/11179	019026 000110US

FORM PCT/DO/EO/916 (371 Formalities Notice)



BIOTECHNOLOGY
SYSTEMS
BRANCH



RAW SEQUENCE LISTING **ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/700,851
Source: PT/09
Date Processed by STIC: 4/22/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE-LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



PCT09

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/700,851

DATE: 04/22/2002
TIME: 15:45:01

Input Set : A:\19026-000110US.app
Output Set: N:\CRF3\04222002\I700851.raw

pg 1-3

Does Not Comply
Corrected Diskette Needed

3 <110> APPLICANT: Matsumoto, Yoh-Ichi
4 Kimura, Tsuyoshi
5 Imaizumi, Atsuchi
6 Takedo, Tae
7 Co, May Sung
8 Vasquez, Maximiliano
9 TEIJIN LIMITED
11 <120> TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE VEROTOXIN II AND
12 CELL LINE PRODUCING SAME
14 <130> FILE REFERENCE: 019026-000110US
16 <140> CURRENT APPLICATION NUMBER: 09/700851
-> 17 <141> CURRENT FILING DATE: 2001-12-18
19 <150> PRIOR APPLICATION NUMBER: WO 99/59629
20 <151> PRIOR FILING DATE: 1999-05-19
22 <150> PRIOR APPLICATION NUMBER: US 60/086,570
23 <151> PRIOR FILING DATE: 1998-05-20
25 <160> NUMBER OF SEQ ID NOS: 8
27 <170> SOFTWARE: PatentIn Ver. 2.1

IGNORED SEQUENCES

80 <210> SEQ ID NO: 2
81 <211> LENGTH: 138
82 <212> TYPE: PRT
83 <213> ORGANISM: Mus musculus
84 <223> OTHER INFORMATION: Figure 1(A): Heavy chain variable region of mouse
85 antibody VTm1.1 (MuVTm1.1).
-> 87 <400> SEQUENCE: 2
88 Met Asn Phe Val Leu Ser Ser Ile Phe Leu Ala Leu Ile Leu Lys Gly
89 1 5 10 15
91 Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys
92 20 25 30
94 Pro Gly Gly Pro Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
95 35 40 45
97 Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu
98 50 55 60
100 Glu Trp Val Ala Thr Ile Ser Thr Gly Gly Ser Tyr Thr Tyr Tyr Pro
101 65 70 75 80
103 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
104 85 90 95
106 Ala Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile
107 100 105 110

(global error)

*This numeric identifier
is mandatory whenever*

✓ C2207 C2217, C2227, or C2237 is shown

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/700,851

DATE: 04/22/2002

TIME: 15:45:01

Input Set : A:\19026-000110US.app

Output Set: N:\CRF3\04222002\I700851.raw

109 Tyr Tyr Cys Ala Arg Arg Gly Asp Ala Trp Gly Asn Leu Asp Tyr Trp
 110 115 120 125

112 Gly Gln Gly Thr Ser Val Thr Val Ser Ser
 113 130 135

164 <210> SEQ ID NO: 4

165 <211> LENGTH: 127

166 <212> TYPE: PRT

167 <213> ORGANISM: Mus musculus <2207

168 <223> OTHER INFORMATION: Figure 1(B): Light chain variable region of mouse

169 VTml.1 antibody (MuVTml.1).

-> 171 <400> SEQUENCE: 4

172 Met Val Phe Thr Pro Gln Ile Leu Gly Leu Met Leu Phe Trp Ile Ser

173 1 5 10 15

175 Ala Ser Arg Gly Asp Val Val Leu Thr Gln Ser Pro Ala Thr Leu Ser

176 20 25 30

178 Val Thr Pro Gly Asp Ser Val Ser Leu Ser Cys Arg Ala Ser Gln Thr

179 35 40 45

181 Ile Ser Asn Asn Leu His Trp Tyr Gln His Lys Ser His Glu Ser Pro

182 50 55 60

184 Arg Leu Leu Ile Lys Ser Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser

185 65 70 75 80

187 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn

188 85 90 95

190 Ser Val Glu Thr Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Tyr

191 100 105 110

193 Ser Trp Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys

194 115 120 125

249 <210> SEQ ID NO: 6

250 <211> LENGTH: 138

251 <212> TYPE: PRT

252 <213> ORGANISM: Mus musculus <2207 insert

253 <223> OTHER INFORMATION: Figure 2(A): Heavy chain variable region of

254 humanized VTml.1 antibody (HuVTml.1).

-> 256 <400> SEQUENCE: 6

257 Met Asn Phe Val Leu Ser Ser Ile Phe Leu Ala Leu Ile Leu Lys Gly

258 1 5 10 15

260 Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln

261 20 25 30

263 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe

264 35 40 45

266 Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu

267 50 55 60

269 Glu Trp Val Ala Thr Ile Ser Thr Gly Gly Ser Tyr Thr Tyr Tyr Pro

270 65 70 75 80

272 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn

273 85 90 95

275 Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val

276 100 105 110

278 Tyr Tyr Cys Ala Arg Arg Gly Asp Ala Trp Gly Asn Leu Asp Tyr Trp

RAW SEQUENCE LISTING

DATE: 04/22/2002

PATENT APPLICATION: US/09/700,851

TIME: 15:45:01

Input Set : A:\19026-000110US.app

Output Set: N:\CRF3\04222002\I700851.raw

```

279          115          120          125
281 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
282          130          135
333 <210> SEQ ID NO: 8
334 <211> LENGTH: 127
335 <212> TYPE: PRT
336 <213> ORGANISM: Mus musculus
337 <223> OTHER INFORMATION: igure 2(B): Light chain variable region of
338 humanized VTml.1 antibody (HuVTml.1)
-> 340 <400> SEQUENCE: 8
341 Met Val Phe Thr Pro Gln Ile Leu Gly Leu Met Leu Phe Trp Ile Ser
342 1 5 10 15
344 Ala Ser Arg Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
345 20 25 30
347 Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr
348 35 40 45
350 Ile Ser Asn Asn Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
351 50 55 60
353 Arg Leu Leu Ile Lys Ser Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala
354 65 70 75 80
356 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
357 85 90 95
359 Ser Leu Glu Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Tyr
360 100 105 110
362 Ser Trp Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
363 115 120 125

```


VERIFICATION SUMMARY

PATENT APPLICATION: US/09/700,851

DATE: 04/22/2002

TIME: 15:45:02

Input Set : A:\19026-000110US.app

Output Set: N:\CRF3\04222002\I700851.raw

7 M:271 C: Current Filing Date differs, Replaced Current Filing Date
7 M:200 E: Mandatory Header Field missing, <220> not found for SEQ ID#:2
71 M:200 E: Mandatory Header Field missing, <220> not found for SEQ ID#:4
56 M:200 E: Mandatory Header Field missing, <220> not found for SEQ ID#:6
40 M:200 E: Mandatory Header Field missing, <220> not found for SEQ ID#:8